CSL Limited

10/17/2024 | Press release | Distributed by Public on 10/17/2024 05:14

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy